Evaluating Indeterminate Interferon‐γ–Release Assay Results in Patients With Chronic Inflammatory Diseases Receiving Immunosuppressive Therapy

摘要: Objective To analyze the rate of indeterminate interferon-γ–release assay (specifically QuantiFeron-TB Gold In-Tube [QFT-GIT]) testing for Mycobacterium tuberculosis in patients with chronic inflammatory disease (CID) compared general hospital population (GH) and a healthy reference group employees (HR), to factors associated an test result. Methods Adults QFT-GIT result within large regional US health system were included. We likelihood having across each patient group. Among CID, we estimated effect glucocorticoids, biologic agents, disease-modifying antirheumatic drug (DMARD) use on test, controlling age, sex, comorbidities, prior services use. Results Of 55,108 who met inclusion criteria, CID made up 5.2% (n = 2,864), GH 48.2%, HR 46.6% study population. Indeterminate results present 5.3% group, 1.9% 1.5% Compared HR, 2.4 times as likely have (adjusted risk ratio [RR] 2.4, 95% confidence interval [95% CI] 1.9–2.9). In adjusted models restricted glucocorticoid significantly increased RR 1.4 CI 1.02–2.0]) while DMARD decreased this 0.7 0.5–0.97]) when not receiving medications. Conclusion Patients more subjects. only was result.